Monkasta (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor 1 (CysLT1). This prevents leukotriene D4 and related mediators from triggering bronchoconstriction, mucus production and inflammatory cell recruitment, thereby stabilising the airways and reducing allergic responses.

The appropriate dose of Monkasta is determined by the prescribing healthcare professional based on the patient’s age, weight, indication and clinical response. Dosage regimens are not disclosed here; patients should follow the prescriber’s instructions.

Safety data for montelukast in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss individual risk factors with the patient.

To request Monkasta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monkasta (montelukast) belongs to the leukotriene receptor antagonist class, which is different from inhaled corticosteroids or long‑acting beta‑agonists. It is taken orally and is useful as add‑on therapy or for patients who cannot tolerate inhaled options, but it does not replace anti‑inflammatory inhalers in moderate‑to‑severe asthma.

Monkasta should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Monkasta is taken orally, usually once daily in the evening, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water; it should not be crushed, chewed or split unless specifically advised.

Serious risks include severe allergic reactions such as angioedema or anaphylaxis, neuropsychiatric events like depression or suicidal thoughts, and hepatic injury. Patients should seek immediate medical attention if they experience rash, mood changes, jaundice or signs of an allergic response.

Monkasta should not be used by individuals with a known hypersensitivity to montelukast or any component of the formulation. Caution is also advised for patients with severe liver impairment, and it is generally avoided in children under the age approved for the specific dosage form.